Toll-free: (877) 631-6311 | Local: (602) 626-3100 |
Office Closed
.(JavaScript must be enabled to view this email address)
My worst call ever

My worst call ever

  • Stephen McBride
  • |
  • Editorial
  • |
  • September 14, 2020

I messed up…

Before the coronavirus outbreak, I doubted telehealth had much potential. I remember sitting outside a café with our publisher and telling him it was a bust.

Trust a quack internet doctor?

No way folks will go for it.

But I’ve done a total 180.

Right now, millions of Americans are firing up their laptops and “visiting” doctors virtually.

In fact, more than 55 million folks now pay for a telehealth subscription.

And industry pioneers Teladoc (TDOC) and Livongo (LVGO)—both previously recommended by my colleague Justin Spittler—have handed out huge gains:

And here’s what I’ve come to realize…

  • The coronavirus is not the real reason telehealth stocks are soaring.

Of course, it shined a spotlight on these stocks. But above all else, telehealth stocks are soaring because they’re doing something totally NEW.

A few years ago, seeing a doctor on the computer wasn’t just “weird.” It was unheard of!

No doctor was willing to write you a prescription over Skype.

Then Teladoc came along and created a marketplace for online medicine. Now a guy in Wyoming can go “see” world-class physicians at the Cleveland Clinic from his living room.

As a RiskHedge reader, you know the moneymaking power of “disruptor” stocks.

There’s only one thing more lucrative than a stock that disrupts a large industry...

And that’s a stock that creates an entirely new industry from scratch.

  • Don’t just take it from me... venture capitalist Peter Thiel has been preaching it too...

Thiel is famous for being “first” to several groundbreaking disruptions.

He founded money disruptor PayPal (PYPL) in the ‘90s. He was also the first outside investor in Facebook (FB). And he backed Airbnb when it was a little-known startup.

A few years back, Thiel wrote an article for the Wall Street Journal titled “Competition Is for Losers.” He pointed out that many of the greatest companies share one thing in common: They’re so far ahead of the game, they have no competitors.

With nothing standing in their way, they have “blue sky” to grow much, much faster than any “regular” business could.

With a multi-year head start and zero competitors... huge profits are theirs for the taking.

  • This played out “to a T” in telehealth.

Remember, seeing your doctor over video chat on the computer wasn’t a thing people did. Teladoc and Livongo essentially created the telehealth industry from scratch.

Teladoc is by far the largest remote medicine platform. Yet it only hosted 2.6 million doctor’s visits in 2018 for patients around the world. That’s a tiny sliver of the 900 million physician visits each year in the US alone.

But then the coronavirus hit the fast-forward button on telehealth. In just the last three months, Teladoc hosted 2.8 million remote visits. That’s more than all of 2018!

And get this... it now has 51 million paying members in the US alone. Telehealth is like the new cable TV!

Meanwhile, Livongo’s sales soared 250%.

With no real competitors, Teladoc and Livongo grabbed all the profits for themselves. And now, they’re joining forces… with Teladoc recently announcing that it’s buying Livongo.

  • Have you heard the saying “what’s scarce is valuable?”

The rarer something is, the more it’s worth.

Most folks understand this for things like diamonds or a Picasso painting. But it’s also true for stocks.

There are only a couple dozen companies creating new industries at any one time. So the value of these stocks typically soars.

Take electric-car pioneer Tesla (TSLA) for example. It’s the most divisive stock on Wall Street, but there’s no debating its incredible performance:

Ditto for the inventor of gaming and AI computer chips, NVIDIA (NVDA). Its stock has surged 4,000%+ in the last decade.

Telehealth stocks are scarce too. 

There weren’t dozens of telehealth stocks to choose from. There were two. And they both minted 250%+ profits in a matter of months.

  • For folks who don’t understand this concept, the speed at which these “new” stocks rise can be puzzling... even shocking...

After all... a 400% gain in a matter of months isn’t something you see in ordinary stocks.

Even disruptor stocks rarely spike that fast. It takes time to disrupt entrenched players. Netflix, for example, disrupted cable... but it took a good 15 years. (Netflix was founded in 1997).

But when you find a disruptor stock that’s doing something entirely NEW... you’ve found something very special:

A stock with blue-sky potential to rise much faster than any ordinary stock could.

Remember: Teledoc and Livongo didn’t try to “disrupt” stodgy old hospitals.

And they didn’t try to be the “next” great healthcare stock like Johnson & Johnson or Pfizer.

Their CEOs weren’t interested in being the “next” anything.

Instead, they were the FIRST telehealth stocks.

The takeaway?

Most investors spend most of their time trying to find the “next” Apple or Amazon.

  • I’m suggesting you approach it differently than the crowd.

Instead of trying to find the “next” Apple...

Hunt for the FIRST ___________.

In future issues, we’ll fill in that blank.

What “new” companies or sectors are you most excited to invest in? Tell me at

Stephen McBride
Editor — Disruption Investor

Stephen McBride is editor of the popular investment advisory Disruption Investor. Stephen and his team hunt for disruptive stocks that are changing the world and making investors wealthy in the process. Go here to discover Stephen’s top “disruptor” stock pick and to try a risk-free subscription.


Did you miss out on the 500%+ profits investors made from Amazon, Netflix, and Nvidia?

If the answer is "Yes," I have something for you... I uncovered three "disruptive" stocks set to double your money. 

Access this special report for FREE
instantly by clicking right here


Get in Touch

PO Box 192495,
Dallas, Texas 75219

Toll-free: (877) 631-6311
Local: (602) 626-3100

Copyright © 2020 Mauldin Economics, LLC. All rights reserved.